Intravenous (IV) Ibuprofen Market Size 2022, Share, Industry Trends & Forecast Till 2027
Intravenous (IV) Ibuprofen Market Overview
IMARC Group has recently released a new research study “intravenous (IV) ibuprofen market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.
What are the growth prospects of the intravenous (IV) ibuprofen Industry?
The global intravenous (IV) ibuprofen market size reached US$ 5.8 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 9.48 Billion by 2027, exhibiting a growth rate (CAGR) of 8.10% during 2022-2027.
What is a intravenous (IV) ibuprofen?
Ibuprofen is associated with the nonsteroidal anti-inflammatory drug (NSAID) class that is used to treat inflammation, pain, fever, etc. It inhibits cyclooxygenase COZ-1 and COX-2 enzymes that are required for the synthesis of prostaglandins (PG). Intravenous (IV) ibuprofen is utilized alone or with other medicines to relieve mild to severe discomfort. It is injected directly into the vein to block the production of certain natural substances that cause inflammation.
Intravenous (IV) ibuprofen aids in reducing narcotic analgesic requirements and lower pain levels with an excellent safety profile. It also assists in improving pain control and minimizing the usage of opioid drugs in orthopedic and abdominal surgeries and fever.
Impact of COVID-19:
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Request and get a sample brochure for free: https://www.imarcgroup.com/intravenous-ibuprofen-market/requestsample
What are the major market drivers in the intravenous (IV) ibuprofen market ?
The rising prevalence of arthritis, cardiovascular diseases (CVDs), cancer, etc., and the expanding geriatric population across countries, are among the key factors stimulating the intravenous (IV) ibuprofen market. Moreover, hectic working schedules and unhealthy lifestyles, as well as a consequent decline in physical activity and proper nutrition, have led to increasing incidences of chronic diseases, which is positively influencing the global market.
Besides this, the widespread adoption of intravenous (IV) ibuprofen to manage rheumatoid disorders, mild to moderate pain, fever, dysmenorrhea, osteoarthritis, etc., is acting as another significant growth-inducing factor. Furthermore, it is also used to treat mild fever, dental pain, gastrointestinal pain, ductus arteriosus in pediatrics, etc., which is propelling the market growth.
Apart from this, continuous improvements in the healthcare infrastructures and the growing consumer health consciousness are expected to fuel the intravenous (IV) ibuprofen market over the forecasted period.
| Intravenous (IV) Ibuprofen Market Report Scope | |
| Report Coverage | Details |
| Market size value in 2021 | US$ 5.8 Billion |
| Market forecast in 2027 | US$ 9.48 Billion |
| Growth Rate | CAGR of 8.10% from 2022 to 2027 |
| Base year for estimation | 2021 |
| Historical data | 2016-2021 |
| Forecast period | 2022-2027 |
| Report coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, And Trends |
| Segments covered | Product Dose, Indication And Age Group |
| Regional scope | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Key companies profiled | Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA and Xgen Pharmaceuticals Djb Inc. |
| Market Dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period, |
| Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Report Segmentation:
The report has segmented the market into the following categories:
Breakup by Product Dose:
- 100 Mg Dose
- 200 Mg Dose
- 400 Mg Dose
- 800 Mg Dose
Breakup by Indication:
- Pain/Inflammatory
- Fever
Breakup by Age Group:
- Pediatrics
- Adults
By Geography:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
List of Major Key Players:
The major players in the market are
- Cumberland Pharmaceuticals Inc.
- Hyloris Pharmaceuticals SA
- Recordati Rare Diseases Inc.
- VALMOR Laboratories CA
- and Xgen Pharmaceuticals Djb Inc.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic, and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology, and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
